Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: The HIVCOBOC-RGT study

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 729-735

  Mandorfer, Mattias ^a,b   Steiner, Sebastian ^a,b   Schwabl, Philipp ^a,b   Payer, Berit A ^a,b   Aichelburg, Maximilian C ^b,c   Lang, Gerold ^b,c   Grabmeier Pfistershammer, Katharina ^b,c   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a,b   Reiberger, Thomas ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vienna HIV Liver Study Group   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Antiviral agents; Boceprevir; Hepatitis C; HIV; Response guided therapy

Indexed keywords

ALPHA2A INTERFERON; ANTIBIOTIC AGENT; BOCEPREVIR; INTERLEUKIN 28B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN; VIRUS RNA;

ABSCESS; ACUTE APPENDICITIS; ADULT; ARTICLE; BACTERIAL INFECTION; CELLULITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER STIFFNESS; MALE; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84942328942     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu516     Document Type: Article

References (34)

1. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-48.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hep-atol 2006;44:S6-9.
3. Konerman MA, Mehta SH, Sutcliffe CG, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014;59:767-75.
4. Mandorfer M, Payer BA, Schwabl P, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int 2014; doi:10.1111/liv. 12615.
5. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
6. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-13.
7. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012;55:728-36.
8. Mandorfer M, Neukam K, Reiberger T, et al. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. AIDS 2013;27:2707-14.
9. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012;13:142-52.
10. Mandorfer M, Payer BA, Niederecker A, et al. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDS 2014;28:221-7.
11. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159:86-96.
12. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13:597-605.
13. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
15. Nelson DR, Poordad F, Feld JJ, et al. High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naïves and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis. J Hepatol 2013;58:S362.
16. Battegay M, Mulcahy F, Geretti AM, et al. European AIDS Clinical Society (EACS) Guidelines Version 7.02. http://www.eacsociety.org/Portals/0/140601-EACS%20EN7.02.pdf. Accessed 21 September 2014.
17. Wedemeyer H, Jensen DM, Godofsky E, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology 2012;56:2398-403.
18. Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma in-ducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012;42:599-606.
19. Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography- A large single center experience. Wiener Klinische Wochenschrift 2012;124:395-402.
20. Vergara S, Macias J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coin-fection. Clin Infect Dis 2007;45:969-74.
21. Mandorfer M, Reiberger T, Payer BA, et al. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. J Viral Hepat 2014;21:33-41.
22. Mandorfer M, Neukam K, Rivero A, et al. Strategies for assignment of HIV/HCV genotype 1-coinfected patients to either dual-therapy or direct-acting antiviral agent based triple therapy. Antivir Ther 2014;19:407-14.
23. Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegy-lated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012;56:788-94.
24. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
25. Beinhardt S, Rutter K, Stattermayer AF, Ferenci P. Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis 2013;56:118-22.
26. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastro-enterology 2012;143:608-18.
27. Neukam K, Barreiro P, Rivero-Juarez A, et al. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. J Infect 2013;67:59-64.
28. Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-inter-feron plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLOS One 2014;9:e94542.
29. Mandorfer M, Payer BA, Scheiner B, et al. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int 2014;34:69-77.
30. Rivero-Juarez A, Neukam K, Labarga P, et al. Sustained virological response in HIV/HCV co-infected patients treated with pegylated inter-feron/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. J Infect 2014;68:372-7.
31. Poizot-Martin I, Bellissant E, Colson P, et al. Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial. http://croiconference.org/sites/all/abstracts/659LB.pdf. Accessed 25 August 2014.
32. Rutter K, Ferlitsch A, Maieron A, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-predictive factors for sepsis. J Hepatol 2013;58:S30.
33. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59:434-41.
34. Payer BA, Reiberger T, Breitenecker F, et al. The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN-+RBV. J Infect 2012;65:142-9.